이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum

2016년 12월 14일 업데이트: Alliance for Clinical Trials in Oncology

A Phase II Trial Of Celecoxib (Celebrex) And Capecitabine (Xeloda) Combined With Pelvic Irradiation As Neoadjuvant Treatment Of Stage II or III Adenocarcinoma Of The Rectum

RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Celecoxib may also make tumor cells more sensitive to chemotherapy and radiation therapy. Giving celecoxib with capecitabine and radiation therapy before surgery may shrink the tumor so that it can be removed.

PURPOSE: This phase II trial is studying how well giving neoadjuvant celecoxib together with capecitabine and pelvic irradiation works in treating patients with stage II or stage III adenocarcinoma (cancer) of the rectum.

연구 개요

상세 설명

OBJECTIVES:

Primary

  • Determine the pathological complete response rate in patients with stage II or III adenocarcinoma of the rectum treated with neoadjuvant celecoxib and capecitabine in combination with pelvic irradiation.

Secondary

  • Determine the safety and tolerability of this regimen in these patients.
  • Determine the rectal function of patients treated with this regimen.
  • Determine the time to recurrence or progression and survival time of patients treated with this regimen.
  • Correlate cellular and molecular markers in pretreatment tumor samples with response in patients treated with this regimen.

OUTLINE: This is a multicenter study.

  • Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7 and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once daily on days 1-5. Courses repeat weekly for 5.5 weeks.
  • Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant chemoradiotherapy.
  • Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses.

Treatment continues in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 1 year and then every 6 months for 4 years.

연구 유형

중재적

등록 (실제)

3

단계

  • 2 단계

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

DISEASE CHARACTERISTICS:

  • Histologically confirmed rectal adenocarcinoma

    • Clinical stage T3, N0, M0 OR any T, N1-3, M0 disease
  • Treatment with neoadjuvant chemotherapy and pelvic radiotherapy is indicated

    • All disease must be encompassable within standard pelvic radiotherapy fields
  • Distal border of the tumor must be at or below* the peritoneal reflection, defined as within 12 cm of the anal verge by endoscopy NOTE: *If a portion of the tumor is below the peritoneal reflection at the time of surgery, patients are eligible regardless of the distance of the tumor determined at endoscopy
  • Tumor must be determined to be clinically resectable

    • Tumor may not be clinically fixed
    • Negative margins by routine examination of an unanesthetized patient
  • Transmural penetration of tumor through the muscularis propria by CT scan, endorectal ultrasound, or MRI
  • No distant metastatic disease

    • No evidence of tumor outside the pelvis, including any of the following:

      • Metastatic inguinal lymphadenopathy
      • Peritoneal seeding
      • Liver metastases

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-1

Life expectancy

  • At least 6 months

Hematopoietic

  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3

Hepatic

  • Bilirubin ≤ upper limit of normal (ULN)
  • AST ≤ 3 times ULN
  • Alkaline phosphatase ≤ 4 times ULN if AST < ULN

Renal

  • Creatinine clearance ≥ 30 mL/min
  • No renal impairment

Cardiovascular

  • No congestive heart failure
  • No symptomatic coronary artery disease
  • No uncontrolled cardiac arrhythmias
  • No myocardial infarction
  • No history of transient ischemic attacks or stroke
  • No other clinically significant cardiac disease

Gastrointestinal

  • No bleeding peptic ulcer disease within the past 12 months
  • No lack of physical integrity of the upper gastrointestinal tract
  • No malabsorption syndrome
  • No active inflammatory bowel disease
  • Must be able to swallow study drugs

Other

  • No dihydropyrimidine dehydrogenase deficiency
  • No history of uncontrolled seizures
  • No CNS disorders
  • No clinically significant psychiatric illness that would preclude study compliance or giving informed consent
  • No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
  • No known sensitivity to NSAIDs, sulfonamides, or aspirin
  • No other serious medical illness that would preclude study treatment
  • No other conditions that would preclude study participation
  • Must be able to tolerate major surgery that may include abdominal-perineal resection
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 30 days after study treatment

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • See Disease Characteristics
  • No prior systemic anticancer chemotherapy

Endocrine therapy

  • Not specified

Radiotherapy

  • See Disease Characteristics
  • No prior radiotherapy to the pelvis

Surgery

  • See Disease Characteristics
  • More than 3 weeks since prior major surgery and recovered

Other

  • At least 7 days since prior nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin
  • No other concurrent investigational drugs
  • No other concurrent anticancer treatment
  • No concurrent NSAIDs
  • No concurrent primary prophylactic therapy for hand-foot syndrome
  • No concurrent loperamide prophylaxis for diarrhea
  • No concurrent sorivudine or brivudine

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: celecoxib + capecitabine + radiation + surgery

Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7 and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once daily on days 1-5. Courses repeat weekly for 5.5 weeks.

Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant chemoradiotherapy.

Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses.

Treatment continues in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 1 year and then every 6 months for 4 years.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
Proportion of successes
기간: Up to 5 years
Up to 5 years

2차 결과 측정

결과 측정
기간
생존 시간
기간: 최대 5년
최대 5년
활착
기간: 최대 5년
최대 5년
Time-to event analyses
기간: Up to 5 years
Up to 5 years
Time to disease progression/recurrence
기간: Up to 5 years
Up to 5 years
Time to recurrence
기간: Up to 5 years
Up to 5 years
Time to first progression
기간: Up to 5 years
Up to 5 years
Bowel function as measured by the Patient Bowel Function (Uniscale) Questionnaire, the FACT Diarrhea Subscale and the Mayo Bowel Function Questionnaire
기간: Up to 5 years
Up to 5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 의자: Frank Sinicrope, MD, Mayo Clinic

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2004년 12월 1일

기본 완료 (실제)

2006년 2월 1일

연구 완료 (실제)

2010년 11월 1일

연구 등록 날짜

최초 제출

2004년 4월 7일

QC 기준을 충족하는 최초 제출

2004년 4월 7일

처음 게시됨 (추정)

2004년 4월 8일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2016년 12월 15일

QC 기준을 충족하는 마지막 업데이트 제출

2016년 12월 14일

마지막으로 확인됨

2016년 12월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다